Cargando…

Tipifarnib in the treatment of acute myeloid leukemia

Farnesyltransferase inhibitors (FTIs) are a new class of biologically active anticancer drugs. The exact anti-tumorigenic mechanism is currently unknown. FTIs inhibit farnesylation of a wide range of target proteins. In preclinical models, tipifarnib (R115777, Zarnestra®), a non-peptidomimetic compe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thomas, Xavier, Elhamri, Mohamed
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2007
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721284/ https://www.ncbi.nlm.nih.gov/pubmed/19707311

Ejemplares similares

Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia
por: Karp, Judith E, et al.
Publicado: (2008)

Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia
por: Raponi, Mitch, et al.
Publicado: (2004)

Identification of tipifarnib sensitivity biomarkers in T-cell acute lymphoblastic leukemia and T-cell lymphoma
por: Alonso-Alonso, Ruth, et al.
Publicado: (2020)

Efficacy of All-Trans-Retinoic Acid in High-Risk Acute Myeloid Leukemia with Overexpression of EVI1
por: Paubelle, Etienne, et al.
Publicado: (2019)

Tipifarnib prevents development of hypoxia-induced pulmonary hypertension
por: Duluc, Lucie, et al.
Publicado: (2017)

Targeting of CD34(+)CD38(-) cells using Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in acute Myeloid Leukaemia
por: Jawad, Mays, et al.
Publicado: (2012)

A Phase 1 Trial Dose Escalation Study of Tipifarnib on a Week-On, Week-Off Schedule in Relapsed, Refractory or High-Risk Myeloid Leukemia
por: Kirschbaum, Mark, et al.
Publicado: (2011)

Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations
por: Ho, Alan L., et al.
Publicado: (2021)

Treatment with Low-Dose Cytarabine in Elderly Patients (Age 70 Years or Older) with Acute Myeloid Leukemia: A Single Institution Experience
por: Heiblig, Maël, et al.
Publicado: (2016)

Tipifarnib and tanespimycin show synergic proapoptotic activity in U937 cells
por: Krzykowska-Petitjean, Katarzyna, et al.
Publicado: (2011)

Lyon-University Hospital Experience with Gemtuzumab Ozogamicin Therapy in Acute Myeloid Leukemia: a ‘Real-Life’ Study
por: Laurino, Marica, et al.
Publicado: (2020)

Acute Myeloid Leukemia in the Elderly Patient: New Strategies
por: Thomas, Xavier
Publicado: (2015)

High frequency of CD34+CD38-/low immature leukemia cells is correlated with unfavorable prognosis in acute myeloid leukemia
por: Plesa, Adriana, et al.
Publicado: (2017)

Immunomodulatory Drugs in Acute Myeloid Leukemia Treatment
por: Piccolomo, Antonio, et al.
Publicado: (2020)

Treatment for Relapsed/Refractory Acute Myeloid Leukemia
por: Thol, Felicitas, et al.
Publicado: (2021)

Treatment of Acute Myeloid Leukemia in Older Adults
por: Alsouqi, Aseel, et al.
Publicado: (2023)

Impact of Genetic Polymorphisms and Biomarkers on the Effectiveness and Toxicity of Treatment of Chronic Myeloid Leukemia and Acute Myeloid Leukemia
por: Alarcón-Payer, Carolina, et al.
Publicado: (2022)

Recent advances in the treatment of acute myeloid leukemia
por: Abdel-Wahab, Omar, et al.
Publicado: (2010)

Acute Myeloid Leukemia: Advancements in Diagnosis and Treatment
por: Yu, Meng-Ge, et al.
Publicado: (2017)

Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment
por: Fenwarth, Laurène, et al.
Publicado: (2020)

Decitabine in the treatment of acute myeloid leukemia in elderly patients
por: Malik, Priya, et al.
Publicado: (2014)

Midostaurin: an emerging treatment for acute myeloid leukemia patients
por: Gallogly, Molly Megan, et al.
Publicado: (2016)

Recent advances in the understanding and treatment of acute myeloid leukemia
por: Watts, Justin, et al.
Publicado: (2018)

Metabolic Plasticity of Acute Myeloid Leukemia
por: Kreitz, Johanna, et al.
Publicado: (2019)

Acute Myeloid Leukemia: Is It T Time?
por: Khoud, Meriem Ben, et al.
Publicado: (2021)

Update on current treatments for adult acute myeloid leukemia: to treat acute myeloid leukemia intensively or non-intensively? That is the question
por: Jaramillo, Sonia, et al.
Publicado: (2023)

A triple combination of atorvastatin, celecoxib and tipifarnib strongly inhibits pancreatic cancer cells and xenograft pancreatic tumors
por: DING, NING, et al.
Publicado: (2014)

Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy
por: Liu, Xiaoming, et al.
Publicado: (2022)

Recent developments in immunotherapy of acute myeloid leukemia
por: Lichtenegger, Felix S., et al.
Publicado: (2017)

Classification of acute myeloid leukemia
por: Hwang, Sang Mee
Publicado: (2020)

The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML)
por: Assouline, Sarit, et al.
Publicado: (2012)

Treatment of Acute Myeloid Leukemia in Adolescent and Young Adult Patients
por: Cengiz Seval, Guldane, et al.
Publicado: (2015)

Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
por: Ramos, Nestor R., et al.
Publicado: (2015)

Targeting Hedgehog (Hh) Pathway for the Acute Myeloid Leukemia Treatment
por: Terao, Toshiki, et al.
Publicado: (2019)

Enasidenib in acute myeloid leukemia: clinical development and perspectives on treatment
por: Reed, Daniel R, et al.
Publicado: (2019)

Mitochondrial metabolism as a target for acute myeloid leukemia treatment
por: Panina, Svetlana B., et al.
Publicado: (2021)

Immunotherapy as a Turning Point in the Treatment of Acute Myeloid Leukemia
por: Aureli, Anna, et al.
Publicado: (2021)

Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia
por: Swaminathan, Mahesh, et al.
Publicado: (2023)

Combination Therapies with Kinase Inhibitors for Acute Myeloid Leukemia Treatment
por: Takahashi, Shinichiro
Publicado: (2023)

Differentiation Therapy of Acute Myeloid Leukemia
por: Gocek, Elzbieta, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_0jo88er3tntp0qi8acle16mm2p